Frontlight ResearchEarly access
Taking people in CzechiaPhase 2
Grafalon for children and young adults recently diagnosed with type 1 diabetes
Compares 2 Grafalon doses in recently diagnosed type 1 diabetes, to protect beta cells.
Key facts
- Who runs it
- Institute For Clinical And Experimental Medicine
- Where
- Prague and Prague 10, CzechiaSee the 2 sites
- Trial code
- EU 2023-508514-42-00
- 2023-506849-29-00
- Registry title
- Grafalon®therapy within 12 weeks of Type 1 diabetes (T1D) diagnosis in children and young adults to prevent the loss of residual beta cell function: a randomised, double-blind, placebo-controlled dose finding study Acronym: GIRO T1D
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 18 people, planned
- Started
- 4 Jun 2024
- Expected to end
- 31 Dec 2028
- Type of study
- Interventional
- Record updated
- 6 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and young adults with recently diagnosed type 1 diabetes. It tests two doses of Grafalon (ATLG) against placebo to protect insulin-making cells.
- Age
- Up to 64 years (the record gives only the maximum age).
- Sex
- All sexes can join.
- Disease stage
- Recent onset type 1 diabetes. The title says treatment starts within 12 weeks of diagnosis.
- Earlier treatment
- Cannot have had other medicines or herbal products that affect the immune system in the 90 days before screening. Cannot have had a vaccination in the 4 weeks before randomization.
Main reasons for not taking part
- HIV, HTLV I/II, hepatitis B or hepatitis C infection
- Positive viral PCR test for EBV, CMV or COVID
- Any past or current cancer
- Pregnant or breastfeeding women, or women who want to become pregnant during the study
- BMI over 35 kg/m2, or another form of diabetes
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- from the beginning of Screening to Visit 14
Who cannot take part
- History of recurrent (e.g., several times a year) of severe (e.g., pneumonia) or chronic infections or conditions predisposing to chronic infections 2. History of severe systemic fungal infection within the past 12 months prior to screening unless treated and resolved with appropriate documented therapy 3. Vaccination within 4 weeks before randomization 4. Positive Viral PCR for EBV, CMV, COVID 5. Patients with HIV or HTLV I/II infection or HepB/C 6. Receipt of any other concomitant medications or herbal products that can influence the immune system within 90 days prior to screening 7. History of pancreatitis (acute or chronic) 8. Any past or current diagnosis of malignant neoplasms 9. Known impairment of the immune system, except for T1D, coeliac disease, alopecia, autoimmune antibodies not considered clinical important (e.g. thyroid antibodies without any clinically important thyroid disease or well-balanced Hashimoto’s disease), and vitiligo 10. Patients with a psychiatric condition (e.g., severe anxiety, psychosis) that would interfere with the study as determined by the primary investigator. Stable psychiatric conditions such as chronic anxiety or depression will be allowed. 11. Patients with known allergy to one or more of the study drug components or rabbit proteins. 12. Female patients who are pregnant, lactating, or who want to get pregnant during the study period. 13. Patients with a history of alcohol or any psychoactive substance abuse or dependence (including alcohol but excluding nicotine and caffeine). 14. Patients with any other significant chronic disease, according to the investigator discretion, exclude rare forms of diabetes (MODY) according to history and clinical judgement. 15. Obesity (BMI more than 35 kg/m2) 16. Other forms of diabetes 17. Patients unable or unwilling to comply with the protocol
Where in Czechia
- Institute for Clinical and Experimental MedicinePrague, CzechiaTaking people
- Fakultní Nemocnice Královské VinohradyPrague 10, CzechiaTaking people
About the trial
What the trial wants to find out
To assess the efficacy and safety of two different ATLG dosages in the treatment of patients with recent onset Type 1 Diabetes.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Grafalon®therapy within 12 weeks of Type 1 diabetes (T1D) diagnosis in children and young adults to prevent the loss of residual beta cell function: a randomised, double-blind, placebo-controlled dose finding study Acronym: GIRO T1D
- Plain-language title
- Grafalon for children and young adults recently diagnosed with type 1 diabetesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 6 May 2026